Denali Therapeutics Inc.
General ticker "DNLI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.8B (TTM average)
Denali Therapeutics Inc. follows the US Stock Market performance with the rate: 53.9%.
Estimated limits based on current volatility of 3.7%: low 19.36$, high 20.85$
Factors to consider:
- Total employees count: 422 (-5.2%) as of 2024
- Top business risk factors: Limited operating history, Significant losses, Operational and conduct risks, Capital market dependence, Intellectual property risks
- Price in estimated range
- Earnings for 15 months up through Q1 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [14.13$, 31.64$]
- 2025-12-31 to 2026-12-31 estimated range: [11.69$, 27.06$]
Financial Metrics affecting the DNLI estimates:
- Negative: with PPE of -8.2 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 89.48 > 64.29
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Industry earnings per price (median), % of -15.38 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term DNLI quotes
Long-term DNLI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $108.46MM | $330.53MM | $0.00MM |
| Operating Expenses | $449.21MM | $527.23MM | $487.34MM |
| Operating Income | $-340.74MM | $-196.70MM | $-487.34MM |
| Non-Operating Income | $14.77MM | $51.51MM | $64.64MM |
| R&D Expense | $358.73MM | $423.88MM | $396.44MM |
| Income(Loss) | $-325.97MM | $-145.19MM | $-422.70MM |
| Taxes | $0.02MM | $0.03MM | $0.07MM |
| Net Income(Loss)* | $-325.99MM | $-145.22MM | $-422.77MM |
| Stockholders Equity | $1,042.43MM | $1,030.95MM | $1,229.68MM |
| Assets | $1,460.24MM | $1,153.92MM | $1,374.18MM |
| Operating Cash Flow | $-244.72MM | $-357.99MM | $-347.69MM |
| Capital expenditure | $17.83MM | $12.94MM | $15.91MM |
| Investing Cash Flow | $-141.39MM | $249.31MM | $-88.76MM |
| Financing Cash Flow | $310.67MM | $17.82MM | $484.30MM |
| Earnings Per Share** | $-2.60 | $-1.06 | $-2.57 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.